SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Nucl Med. 2008; 49 (Supplement 1):35P
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Rowe, C.
Right arrow Articles by Villemagne, V.
PubMed
Right arrow Articles by Rowe, C.
Right arrow Articles by Villemagne, V.

Neurosciences: Neurology

Dementia II - Differential Diagnosis and Follow Up

Beta-amyloid imaging with 18F-BAY94-9172 (AV1/ZK) PET in the differential diagnosis of Alzheimer’s disease from fronto-temporal lobar degeneration

Christopher Rowe1, Uwe Ackermann1, Rachel Mulligan1, Graeme O'Keefe1, Hank Kung2, Daniel Skovronsky3, Thomas Dyrks4, Ludger Dinkelborg4, Colin Masters5 and Victor Villemagne1

1 Centre for PET, Austin Hospital, Melbourne, Victoria, Australia; ; 2 Radiology, University of Pennsylvania, Philadelphia, Pennsylvania; ; 3 Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania; ; 4 Bayer Schering Pharma, Berlin, Germany; ; 5 The Mental Health Research Institute, University of Melbourne, Melbourne, Victoria, Australia

138

Objectives: Clinical distinction between Alzheimer’s disease (AD) and Frontotemporal lobar degeneration (FTLD) is inaccurate. Beta-amyloid (Aβ) imaging with 11C-PiB PET can distinguish AD (extensive Aβ) from FTLD (no Aβ) but the short half-life of carbon-11 is problematic for clinical use. The purpose of this study was to compare patients with AD to patients with FTLD and age matched healthy controls (HC) using 18F-BAY94-9172, a novel 18F labelled, stilbene based, Aβ radioligand

Methods: Fifteen HC, 5 FTLD and 15 AD patients with mild to moderate dementia, underwent PET imaging with 300 MBq 18F-BAY94-9172. Standardized Uptake Volume ratios (SUVR) were calculated using the cerebellum as reference region 90-120 min PI

Results: All AD subjects showed extensive cortical binding. There was no cortical uptake in most FTLD or HC subjects. One FTLD (semantic dementia subtype) and three HC showed mild cortical binding but less than in AD. Higher SUVR in neocortical areas were observed in AD (2.02±0.28) when compared with HC (1.29±0.17) and FTLD (1.22±0.17)

Conclusions: In contrast to AD, most FTLD subjects show no cortical 18F-BAY94-9172 binding consistent with both histopathological and 11C-PiB PET studies of Aβ in these conditions. 18F-BAY94-9172 PET should assist in the diagnosis of AD from FTLD. The robust visual findings, simplicity of the semiquantitative approach and the longer radioactive half-life are well suited to clinical use

Research Support: Bayer Schering Pharma, NHMRC Grant 509166





Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Rowe, C.
Right arrow Articles by Villemagne, V.
PubMed
Right arrow Articles by Rowe, C.
Right arrow Articles by Villemagne, V.